Evidence map›Paper›PMID 34104201›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

The Effect of a Persian Herbal Medicine Compound on the Lipid Profiles of Patients with Dyslipidemia: A Randomized Double-Blind Placebo-Controlled Clinical Trial.

Alireza Niknafs, Mohammadreza Rezvanfar, Mohammad Kamalinejad, Seyed Amirhosein Latifi, Amir Almasi-Hashiani, Mehdi Salehi

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Effects ofIranian journal of basic medical sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alireza NiknafsTraditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran.
Mohammadreza RezvanfarEndocrinology and Metabolism Research Center, Department of Internal Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Mohammad KamalinejadSchool of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran.
Seyed Amirhosein LatifiTraditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran.
Amir Almasi-HashianiDepartment of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.
Mehdi SalehiTraditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran.ORCID https://orcid.org/0000-0001-6114-0646
Arak University of Medical Sciences · IRShahid Beheshti University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIt has been well established in the world that lipid disorders promote the development of atherosclerosis and its clinical consequences. This study aimed to assess the impacts of a Persian medicinal (PM) compound on lipid profile. MATERIALS AND

methodsFrom June 21 to October 21, 2020, a randomized double-blind controlled clinical trial was conducted with 74 dyslipidemic patients, who were randomly divided into two equally populated groups: one prescribed with a Persian medicinal herbal compound (

resultsPercent changes of biochemical parameters include the following: intervention group = cholesterol: 35.22, Tg: 45.91, LDL: 24.81, HDL: 2.05, VLDL: 8.94 and placebo group = cholesterol: 6.94, Tg: -7.3, LDL: 7.37, HDL: 2.88, VLDL: -0.14. The serum levels of total cholesterol (

conclusionThis study showed that a Persian medicinal herbal compound could be safe and beneficial to decrease the levels of serum cholesterol and LDL in dyslipidemic patients. However, larger long-term studies are recommended to clarify this effect.

Identifiers

PMID34104201
PMCPMC8159633
OpenAlexW3161878092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.